Non-selective endothelin receptor antagonist for ET-A and ET-B receptors and accordingly, the pathological bone ET-1 levels increased with osteoporosis returned to normal levels with the reduction of bone ET-1 in both doses of bosentan. This evidence concerns the gene EDNRA and osteoporosis.